No Data
No Data
Express News | Alnylam Announces Retirement of Longtime Board Member, DR. Phillip a. Sharp, Company Co-Founder and Industry Luminary
Alnylam Announces Retirement of Longtime Board Member, Dr. Phillip A. Sharp, Company Co-Founder and Industry Luminary
CCORF Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $385
Alnylam Pharmaceuticals: Balancing Promising Pipeline With Competitive Challenges and Strategic Uncertainties
Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 20 Years
BMO Capital Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $300